Board of Directors

Craig A. Collard has served as president and chief executive officer and the chairman of the board of directors since our merger with Cornerstone BioPharma in October 2008. In March 2004, Mr. Collard founded Cornerstone BioPharma Holdings, Ltd., the assets and operations of which were restructured as Cornerstone BioPharma in May 2005, and served as its president and chief executive officer, and as director from March 2004 to October 2008. Before founding Cornerstone BioPharma, Mr. Collard served as the president and chief executive officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company he founded in May 2003. From August 2002 to February 2003, Mr. Collard served as vice president of sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company based in the Research Triangle Park, N.C. From 1998 to 2002, Mr. Collard worked as director of national accounts at DJ Pharma, Inc., a specialty pharmaceutical company which was eventually purchased by Biovail Pharmaceuticals, Inc. His pharmaceutical career began in 1992 as a field sales representative at Dura Pharmaceuticals, Inc. He was later promoted to several other sales and marketing positions within Dura. Mr. Collard is a member of the board of directors of Hilltop Home Foundation, a non-profit corporation in Raleigh, NC. Mr. Collard holds a B.S. in engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, GA.

Michael Heffernan has served on the board of directors since the merger with Cornerstone BioPharma. Since 2002, Mr. Heffernan has served as president and chief executive officer of Collegium Pharmaceutical, Inc., a specialty pharmaceutical company that develops and commercializes products to treat central nervous system, respiratory and skin-related disorders. From 1999 to 2001, Mr. Heffernan served as president and chief executive officer of PhyMatrix Corp., an integrated healthcare services company. From 1995 to 1999, Mr. Heffernan served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical clinical development company. From 1987 to 1994, Mr. Heffernan served in a variety of sales and marketing positions with Eli Lilly and Company, a pharmaceutical company. Mr. Heffernan has also served on the board of directors for TyRx Pharma, Inc. since 2002. Mr. Heffernan holds a B.S. in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

Christopher Codeanne has served on the board of directors since the merger with Cornerstone BioPharma. Since April 2008, Mr. Codeanne has served as chief operating officer and chief financial officer of Oncology Development Partners, LLC (d/b/a Oncopartners), a specialized international oncology contract research organization. From December 2006 through April 2008, Mr. Codeanne served as the chief financial officer of Averion International Corp., a publicly traded international contract research organization. Prior to Averion, from 2002 through July 2006, Mr. Codeanne was the chief financial officer of SCIREX Corporation (which was acquired by Premier Research Group plc in 2006), an international, full-service clinical research organization. From 1999 to 2002, Mr. Codeanne served as director of finance for SCIREX. Mr. Codeanne is a member of the American Institute of Certified Public Accountants, the Connecticut Society of Certified Public Accountants and Financial Executives International. Mr. Codeanne holds a B.A. in Accounting from Fairfield University and an MBA from the University of Connecticut.

Michael Enright has served on the board of directors since the merger with Cornerstone BioPharma. Since 1995, Mr. Enright has served as chief financial officer for Atlantic Search Group, Inc., a staff augmentation and functional outsourcing services organization serving pharmaceutical companies and contract research organizations in the United States and India. Prior to 1995, Mr. Enright held positions in employee benefits administration with Hauser Insurance Group and The Prudential Insurance Company, and in financial management with General Electric Company’s aerospace business group. Mr. Enright holds a B.A. in Finance from Villanova University and an MBA from the Kenan-Flagler School of Business of the University of North Carolina at Chapel Hill.